While the FDA could regulate diagnostic tests the way they are in Europe-through simple verification that the test is accurate-the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.
While the FDA could regulate diagnostic tests the way they are in Europe—through simple verification that the test is accurate—the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.
Transcript (slightly modified)
What shoud the FDA be focusing on more when it comes to diagnostic testing: clinical utility or clinical validity?
It depends what paradigm the FDA wants to use. The model that's used in Europe is simply to verify that the test is accurate. And for that reason a lot of kits are CE marked in Europe, they're used in the United Kingdom, they're used in Canada long before they're available in the United States, because they've simply proved that the test is accurate: it can detect these 5 mutations or those 7 mutations.
Although the FDA could do that, it has paired the approval with the actual drug activity for most combination diagnostics. So if a gene is known to be paired with a drug, they won't let you just produce an accurate genetic test by itself. The FDA requires it to be closely correlated with the drug outcome. I think we would solve a lot of problems if for those genetic tests we simply asked that the test be accurate, which is the standard that's used in Europe.
One of the issues for the FDA that brings it much closer to clinical utility, even if they don't use the word, is if they're looking at risk and benefit. And once you define the risk as being certain bad outcomes or certain disadvantages, you have to define the benefit to counterbalance that, and the benefit is really a clinical utility. It's something that's beneficial to the patient.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More